Baird’s AbbVie ABBV Stock Holding History

Baird’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	$116M	Buy	1,978,156 +1,083,288	+121%	+$65.4M	1.18%	7
2014 Q4	$58.6M	Buy	894,868 +589,179	+193%	+$37.1M	0.62%	25
2014 Q3	$17.7M	Sell	305,689 -62,267	-17%	-$3.46M	0.25%	120
2014 Q2	$20.8M	Sell	367,956 -16,632	-4%	-$873K	0.29%	101
2014 Q1	$19.8M	Sell	384,588 -19,395	-5%	-$980K	0.29%	103
2013 Q4	$21.3M	Buy	403,983 +23,980	+6%	+$1.18M	0.37%	61
2013 Q3	$17M	Buy	380,003 +7,094	+2%	+$314K	0.32%	75
2013 Q2	$15.4M	Buy	+372,909	New	+$16.3M	0.31%	77

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Baird's ABBV Position: Q1 2015 in Review

Baird increased its AbbVie (ABBV) stake by 121% in Q1 2015, buying an estimated $65.4M and bringing the position to 1,978,156 shares worth $116M. The position accounts for 1.18% of the portfolio, ranked #7.

Baird first reported a position in ABBV in Q2 2013 and has held it in 8 quarters since. 1,600 funds tracked by Wall St. Rank hold ABBV as of Q1 2015.

Baird held 1,978,156 shares of AbbVie worth $116M as of Q1 2015.
Baird bought 1,083,288 AbbVie shares in Q1 2015, an estimated $65.4M.
AbbVie made up 1.18% of Baird's portfolio in Q1 2015, its #7 holding.
Baird first reported a position in AbbVie in Q2 2013 and has held it in 8 quarters since.
1,600 funds tracked by Wall St. Rank held AbbVie as of Q1 2015.

Based on Baird's 13F filing for Q1 2015, filed 13 May 2015.